- Home
- HQI vs IKT Comparison
HQI vs IKT Comparison
Compare HQI & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- IKT
- Stock Information
- Founded
- HQI 2002
- IKT 2008
- Country
- HQI United States
- IKT United States
- Employees
- HQI N/A
- IKT N/A
- Industry
- HQI Professional Services
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- HQI Consumer Discretionary
- IKT Health Care
- Exchange
- HQI Nasdaq
- IKT Nasdaq
- Market Cap
- HQI 140.2M
- IKT 140.5M
- IPO Year
- HQI N/A
- IKT 2020
- Fundamental
- Price
- HQI $9.98
- IKT $1.66
- Analyst Decision
- HQI Buy
- IKT Buy
- Analyst Count
- HQI 1
- IKT 2
- Target Price
- HQI $13.00
- IKT $8.00
- AVG Volume (30 Days)
- HQI 7.1K
- IKT 97.5K
- Earning Date
- HQI 11-06-2025
- IKT 08-14-2025
- Dividend Yield
- HQI 2.41%
- IKT N/A
- EPS Growth
- HQI N/A
- IKT N/A
- EPS
- HQI 0.17
- IKT N/A
- Revenue
- HQI $32,610,000.00
- IKT N/A
- Revenue This Year
- HQI N/A
- IKT N/A
- Revenue Next Year
- HQI $5.13
- IKT N/A
- P/E Ratio
- HQI $57.00
- IKT N/A
- Revenue Growth
- HQI N/A
- IKT N/A
- 52 Week Low
- HQI $8.94
- IKT $1.12
- 52 Week High
- HQI $15.75
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- HQI 54.70
- IKT 45.73
- Support Level
- HQI $9.66
- IKT $1.66
- Resistance Level
- HQI $10.07
- IKT $1.87
- Average True Range (ATR)
- HQI 0.32
- IKT 0.10
- MACD
- HQI 0.07
- IKT -0.01
- Stochastic Oscillator
- HQI 90.53
- IKT 33.82
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.